Card | Preventing relapse | Preventing disease progression | Side effect risk | Route of administration | Frequency of administration |
---|---|---|---|---|---|
A | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 5 years | Rare but severe life-threatening side effects (including PML) | Oral | Daily |
B | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 2 years | Frequent but mild/moderate side effects | Subcutaneous– intramuscular | Daily |
C | Presenting a relapse every 5 years | Preventing the disease from getting worse/progressing for 5 years | Rare but severe life-threatening side effects (including PML) | Intravenous | Daily |
D | Presenting a relapse every 5 years | Preventing the disease from getting worse/progressing for 2 years | Frequent but mild/moderate side effects | Oral | Every 2 days—weekly |
E | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 5 years | Rare but severe life-threatening side effects (including PML) | Subcutaneous– intramuscular | Every 2 days—weekly |
F | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 5 years | Rare but severe life-threatening side effects (including PML) | Oral | Monthly |
G | Presenting a relapse every 5 years | Preventing the disease from getting worse/progressing for 2 years | Rare but severe life-threatening side effects (including PML) | Subcutaneous– intramuscular | Monthly |
H | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 5 years | Frequent but mild/moderate side effects | Intravenous | Monthly |
I | Presenting a relapse every 5 years | Preventing the disease from getting worse/progressing for 5 years | Frequent but mild/moderate side effects | Subcutaneous– intramuscular | Twice per year |
J | Presenting a relapse every 2 years | Preventing the disease from getting worse/progressing for 2 years | Rare but severe life-threatening side effects (including PML) | Intravenous | Twice per year |